Vai al contenuto principale della pagina

Antibody Drug Conjugates : Design, Discovery, and Development / / edited by Hovhannes J. Gukasyan, Ashutosh Kulkarni



(Visualizza in formato marc)    (Visualizza in BIBFRAME)

Autore: Gukasyan Hovhannes J Visualizza persona
Titolo: Antibody Drug Conjugates : Design, Discovery, and Development / / edited by Hovhannes J. Gukasyan, Ashutosh Kulkarni Visualizza cluster
Pubblicazione: Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2026
Edizione: 1st ed. 2026.
Descrizione fisica: 1 online resource (306 pages)
Disciplina: 615.36
Soggetto topico: Pharmacology
Pharmacy
Pharmaceutical chemistry
Pharmaceutics
Altri autori: Gukasyan  
Nota di contenuto: Commercialized ADCs: A Market Snapshot for Exemplification -- Application of ADCs to Therapeutic Areas Outside of Oncology -- Regulatory framework for the manufacturing and marketing of ADCs -- Conjugation Chemistry and Chemical Design for the Discovery and Development of Antibody Drug Conjugates -- Clinical Pharmacology Considerations in Antibody-Drug Conjugates Development -- Bioanalytical Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugates -- Toxicology Considerations on Antibody-Drug Conjugate Discovery and Development -- Considerations for Antibody Drug Conjugate Design Stability and Formulation.
Sommario/riassunto: This volume provides a comprehensive recapitulation of structure-activity relationship (SAR) from a mechanism of action point of view for this unique therapeutic modality, in a largely disease agnostic manner. From a disease biology and pharmacology perspective, the cellular target and drug-conjugate selection, considerations on liker -chemistry and -antibody ratio, and formulation science and technology, to get from bench to bedside (i.e. from a laboratory to the systemic circulation in a patient). The book also provides an understanding around target binding and drug/"payload" release mechanisms. Furthermore, pharmacokinetic and safety pharmacological aspects from a regulatory and clinical perspective are discussed, along with current chemistry, manufacturing, controls guidance and emerging novel delivery devices or technologies. The key differentiation in Antibody Drug Conjugates is the clinical and development discussion, that offers pragmatic considerations in medical product development, IP, regulatory considerations, among others. Furthermore, we discuss the topic as a platform, in a disease agnostic manner.
Titolo autorizzato: Antibody Drug Conjugates  Visualizza cluster
ISBN: 3-031-89319-0
Formato: Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione: Inglese
Record Nr.: 9911049063503321
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Serie: AAPS Advances in the Pharmaceutical Sciences Series, . 2210-738X ; ; 52